Recent Finacing
Recent Raise
Forbius is a clinical-stage protein engineering company developing TGF‑β‑selective inhibitors (AVID200) and an anti‑EGFR antibody‑drug conjugate (AVID100) for fibrotic and EGFR‑overexpressing cancers.
Focus Areas
Recent Investors
Total Raised
Funding rounds
Investors
See the team members at Forbius.
